US proposes steep tariffs on branded pharmaceuticals, intensifying global drug pricing tensions
Original framing: “US plans tariffs up to 100% on some brand-name drugs” — Phys.org
Scientific evidence shows that high drug prices do not necessarily correlate with innovation or quality. Studies indicate that pharmaceutical companies often spend more on marketing than on research and development.
The proposed US tariffs on brand-name drugs are not simply a trade issue but a reflection of deeper systemic problems in global pharmaceutical policy.
Patent monopolies, corporate lobbying, and the lack of price regulation have created a system where drug prices are disconnected from cost and innovation. Cross-culturally, alternative models such as generic production and price regulation offer viable solutions. By integrating scientific evidence, historical context, and marginalized voices, we can move toward a more equitable and sustainable global health system. International cooperation and legal reform are essential to shift the balance of power from pharmaceutical corporations to public health.